1.Advances in researches on epididymal WFDC-type serine protease inhibitors.
Juan LIU ; Hai-Yan WANG ; Jian-Yuan LI
National Journal of Andrology 2008;14(11):1027-1030
Sperm maturation in the epididymis is regulated by changes of luminal ion concentration and processing of sperm surface membrane by several glycosidases and proteases, and the actions of the proteases are controlled by protease inhibitors present in specific areas of the epididymis. WFDC-type serine protease inhibitors that are highly expressed in the epididymis play an important role in natural immunity and male reproduction. This paper gives an overview of the structure and function of the protein and its application prospects in the development of drugs for male reproductive tract infection and immunocontraception.
Anti-Infective Agents
;
therapeutic use
;
Contraceptive Agents
;
Epididymal Secretory Proteins
;
metabolism
;
Epididymis
;
chemistry
;
metabolism
;
Humans
;
Male
;
Serine Proteinase Inhibitors
;
genetics
;
metabolism
;
therapeutic use
2.Could Nafamostat or Gabexate Prevent the Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis?.
Yong Hwan KWON ; Ji Yeon KIM ; Sang Jik LEE ; Se Young JANG ; Hyun Woo PARK ; Hae Min YANG ; Min Kyu JUNG ; Seong Woo JEON ; Chang Min CHO ; Won Young TAK ; Young Oh KWEON ; Sung Kook KIM
The Korean Journal of Gastroenterology 2012;59(3):232-238
BACKGROUND/AIMS: ERCP is the most common procedure for the diagnosis and treatment of bile duct and pancreatic disease, but Post-ERCP pancreatitis makes poor outcome in some cases. The protease inhibitors, nafamostat and gabexate, have been used to prevent pancreatitis related to ERCP, but there is some debate. We tried to evaluate the efficacy of gabexate and nafamostat for the prevention of post-ERCP pancreatitis. METHODS: Two hundred forty two patients (73 patients in the gabexate group, 88 patients in the nafamostat group and 81 patients in the placebo group) were included in the study after selective exclusion. The incidence of pancreatitis after ERCP was compared among groups. RESULTS: The incidence of pancreatitis were 6.8% in the gabexate group, 5.7% in the nafamostat group and 6.2% in the placebo group (p=0.954). CONCLUSIONS: There was no meaningful difference among the gabexate, nafamostat and placebo group.
Adult
;
Aged
;
Aged, 80 and over
;
Cholangiopancreatography, Endoscopic Retrograde/*adverse effects
;
Female
;
Gabexate/*therapeutic use
;
Guanidines/*therapeutic use
;
Humans
;
Male
;
Middle Aged
;
Pancreatitis/etiology/*prevention & control
;
Placebo Effect
;
Questionnaires
;
Serine Proteinase Inhibitors/*therapeutic use
;
Young Adult
3.Research progress of the small molecule covalent inhibitors.
Bo YANG ; Wen-Jing WANG ; Lin-Li LI
Acta Pharmaceutica Sinica 2014;49(2):158-165
Small molecule covalent inhibitors, or called as irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity. Nevertheless, these agents may also exhibit larger toxicity once off-target effects arise. This "double-edged swords" property often leads drug researchers to avoid attaching them. In recent years, some problems such as drug resistance are difficult to be solved with reversible inhibitors leading researchers to pay more attention on the covalent inhibitors. In this review, we shall make a short summary to the recent research progress of covalent inhibitors and the interaction modes between covalent inhibitors and their target protein residues.
Amino Acids
;
chemistry
;
Antineoplastic Agents
;
chemical synthesis
;
chemistry
;
therapeutic use
;
Antiviral Agents
;
chemical synthesis
;
chemistry
;
therapeutic use
;
Drug Discovery
;
Drug Resistance
;
Enzyme Inhibitors
;
chemical synthesis
;
chemistry
;
therapeutic use
;
Hepatitis C
;
drug therapy
;
Humans
;
Molecular Structure
;
Neoplasms
;
drug therapy
;
Protein Binding
;
Protein Kinase Inhibitors
;
chemical synthesis
;
chemistry
;
therapeutic use
;
Receptor, Epidermal Growth Factor
;
antagonists & inhibitors
;
Serine Proteinase Inhibitors
;
chemical synthesis
;
chemistry
;
therapeutic use